Media & Press Releases

TORREY PINES, CA, May 27, 2022 -- EpicentRx, Inc, a privately-held clinical-stage biotechnology company at the forefront of oncolytic viruses and small molecules for the treatment of cancer and other inflammatory-driven diseases, today announced that data from a Phase...

TORREY PINES, CA, May 10, 2022 — EpicentRx, Inc., a privately-held clinical-stage biotechnology company at the forefront of oncolytic viruses and small molecules for the treatment of cancer and other inflammatory-driven diseases, today announced that it has been...

Phase 1 trial with cancer-targeting adenovirus enhanced with a TGFβ Trap continues to investigate safety and anti-tumor activity in patients with advanced cancer TORREY PINES, CA, April 21, 2022 – EpicentRx Inc., a leading-edge immunotherapy company using...

TORREY PINES, CA., February 23, 2022 – EpicentRx, Inc., a clinical stage drug and device company, in collaboration with the Texas Children's Cancer Center in Houston, today announced the start of a Phase 1 study to examine the safety and benefit of its lead small...

Collaboration builds on recent data presented by Actinium at SITC demonstrating enhanced activity of targeted radiotherapies in combination with the anti-CD47 targeting antibody magrolimab in blood cancer and solid tumor models Collaboration to explore Actinium’s...

Oncolytic Adenovirus in Phase 1 has extended half-life TGF-ß trap LA JOLLA, Calif., December 8, 2021 -- EpicentRx, Inc., a clinical-stage biotechnology company at the forefront of oncolytic viruses and small molecules for the treatment of cancer and other...

LA JOLLA, Calif., Nov. 22, 2021 -- EpicentRx, Inc., a clinical-stage biotechnology company at the forefront of oncolytic viruses and small molecules for the treatment of cancer and other inflammatory-driven diseases, today announced that the United States Patent and...

Cancer-targeting adenovirus enhanced with a TGFβ Trap well tolerated in patients with advanced cancer TORREY PINES, Calif., Sept. 29, 2021 -- EpicentRx Inc., a leading-edge drug and device company with cancer and inflammatory disease-targeted platforms, today...

Company secures 10M US dollar growth capital term loan from Silicon Valley Bank (SVB) to accelerate development of immunotherapies for cancer AdAPT-001, a TGF-beta trap expressing oncolytic virus, designed to activate the immune system and improve checkpoint...

SciClone granted exclusive license to co-develop and commercialize RRx-001 upon approval in the Greater China Region LA JOLLA, Calif., July 1, 2020 -- EpicentRx Inc. ("EpicentRx"), a San Diego-based clinical cancer immunotherapy company and SciClone Pharmaceuticals...

TORREY PINES, Calif., June 10, 2020 -- EpicentRx, Inc., a clinical-stage pharmaceutical company on a mission to advance its portfolio of small molecule and virus-based immunotherapies for the treatment of patients with cancer and other diseases of high unmet need such...

TORREY PINES, Calif., May 29, 2020 -- EpicentRx, a next-generation clinical immuno-oncology company, today announced the appointment of physician, scientist and businessman Tony Reid, M.D., Ph.D., as the company's chief executive officer. Dr. Reid who is a co-founder...

EpicentRx’s lead program is the first-in-class small molecule CD47 antagonist RRx-001 in Phase 3 for small cell lung cancer Enrollment of Phase I trial for adenovirus program AIM-001 expected to begin this year Close of recent $35M series D will advance AIM-001 and...

TORREY PINES, Calif., June 10, 2020 -- EpicentRx, Inc., a clinical-stage pharmaceutical company on a mission to advance its portfolio of small molecule and virus-based immunotherapies for the treatment of patients with cancer and other diseases of high unmet need such...

RRx-001 led to an overall survival of 21.9 months and progression-free survival of 13 months Data presented at the Society for Neuro-Oncology annual meeting LA JOLLA, Calif. -- EpicentRx, Inc., a clinical cancer immunotherapy company targeting both sides of the immune...

Series D Funded by an undisclosed source from Europe Total capital raised by EpicentRx approximately $77 million LA JOLLA, Calif. -- EpicentRx, Inc., a clinical cancer immunotherapy company targeting both sides of the immune system to deliver cancer treatments with...

LA JOLLA, Calif. -- EpicentRx, Inc., a clinical cancer immunotherapy company targeting both sides of the immune system to deliver cancer treatments with minimal toxicity, announced today that it has dosed the first patient in the Phase 3 REPLATINUM trial evaluating...

LA JOLLA, Calif., June 25, 2019 -- EpicentRx Inc., a clinical-stage immuno-oncology company with two platforms developed to prime and activate both innate and adaptive anticancer responses, today announced the publication of positive results from its Phase 2 clinical...